Oxaliplatin Injection, Solution
Product Images NDC 60505-6132

This appears to be a graph or table with data related to "DFS Probability" and "Hazard Ratio" with information about the number of events, patient risk, and a stratified logrank test. Without more context or a clear image, it is difficult to provide a more specific description.*

This appears to be a table of data related to DFS (Disease Free Survival) probability, with rows representing different time periods (in months) and columns representing different stages of the disease. There is also information about treatment arm and a statistical test result.*

This text provides a comparison of two treatments for cancer patients in terms of their median survival rates and the percentage of patients surviving. The first treatment is a combination of Oxaliplatin Injection USP and 5-FULV, which has a median survival rate of 19.4 months. The second treatment is a combination of Oxaliplatin Injection USP and irinotecan, which has a median survival rate of 17.6 months. The text also mentions a statistical test conducted to compare the two treatments, which resulted in a p-value of less than 0.0001. However, the specific type of cancer being treated and any potential side effects of the treatments are not provided.*

This is a description of a medication with a strength of 50 mg, containing oxaliplatin, manufactured by Qilu Pharmaceutical (Hainar) Co., Ltd. It is available in a single-dose vial with a volume of 10 mL, with a concentration of 5 mg/mL, and has a lot number of 00000000. It has an expiration date of 10/2022, and is sterile and preservative-free. The medication is an injection, and the manufacturer is Apotex Corp., located in Weston, Florida, USA. The medication is sold under NDC 60505-6132-6.*

Oxaliplatin Injection is a single dose vial for intravenous use. The solution contains a cytotoxic agent and should not be mixed with sodium chloride or chloride-containing solutions. The package insert provides dosing and administration instructions as well as required dilution details. Each vial contains 100mg of Oxaliplatin and water for injection. It should be stored at controlled room temperature and protected from light. Unused portions should be discarded as instructed in the package insert. The manufacturer is Qilu Pharmaceutical (Hainan) Co., Ltd. and it is distributed by Apotex Corp. in Weston, Florida.*

This is a description for a medication with the product identifier NDC 60505-6132-8. It is a single-dose vial injection of 200mg strength, which should only be used intravenously. The solution is sterile, aqueous, and does not contain preservatives. Further dilution is required, as specified in the package insert. The medication should not be mixed with or added to any chloride-containing solutions. Its manufacturer is Qilu Pharmaceutical located in Haikou, China, and it is manufactured for Apotex Corp. based in Florida, USA. The medication has an expiration date of 05/2022, and its lot number is EB1W0000.*

This is a description of a medication called Oxaliplatin Injection, USP manufactured by Apotex Corp. The medication comes in a single-dose vial that contains 200mg/0ml. It is for intravenous use only and should be stored at 25°C (77°F). The medication is used for dosage and administration purposes. Excursions are limited between 15-30°C (59 to 86°F). The package insert contains more information about how to use and store the medication.*